Pure Global

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression - Trial NCT04569032

Access comprehensive clinical trial information for NCT04569032 through Pure Global AI's free database. This Phase 2 trial is sponsored by Seagen Inc. and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04569032
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT04569032
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

Study Focus

brentuximab vedotin

Interventional

drug

Sponsor & Location

Seagen Inc.

Birmingham,Stanford,Aurora,Aurora,Washington,Niles,New Orleans,New Orleans,Ann Arbor,New York,Cleveland,Fairfield,Knoxville,Amarillo,Austin,Fort Worth,Houston,Longview,Richmond,Virginia Beach,Cedex 9,, France,Italy,Spain,United Kingdom,United States of America

Timeline & Enrollment

Phase 2

Nov 12, 2020

Dec 31, 2023

80 participants

Primary Outcome

Objective response rate (ORR) per blinded independent central review (BICR) using Revised Response Criteria for Malignant Lymphoma criteria (Cheson 2007)

Summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for
 people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out
 what side effects occur when brentuximab vedotin and CHP are used together. A side effect is
 anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three
 drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat
 certain types of PTCL.

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

ClinicalTrials.gov

NCT04569032

Non-Device Trial